A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Trial Profile

A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 May 2017 Planned number of patients changed from 12 to 44.
    • 13 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 13 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top